These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 12939207

  • 1. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
    Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R, Valsartan Heart Failure Trial Investigators.
    Circulation; 2003 Sep 16; 108(11):1306-9. PubMed ID: 12939207
    [Abstract] [Full Text] [Related]

  • 2. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators.
    N Engl J Med; 2001 Dec 06; 345(23):1667-75. PubMed ID: 11759645
    [Abstract] [Full Text] [Related]

  • 3. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 4. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.
    Am Heart J; 2004 Jul 20; 148(1):122-8. PubMed ID: 15215801
    [Abstract] [Full Text] [Related]

  • 5. Effect of Valsartan on hospitalization: results from Val-HeFT.
    Carson P, Tognoni G, Cohn JN.
    J Card Fail; 2003 Jun 20; 9(3):164-71. PubMed ID: 12815565
    [Abstract] [Full Text] [Related]

  • 6. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
    Baruch L, Glazer RD, Aknay N, Vanhaecke J, Heywood JT, Anand I, Krum H, Hester A, Cohn JN.
    Am Heart J; 2004 Dec 20; 148(6):951-7. PubMed ID: 15632877
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 20; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 8. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN.
    Circ Heart Fail; 2008 May 20; 1(1):34-42. PubMed ID: 19808268
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
    De Tommasi E, Iacoviello M, Romito R, Ceconi C, Guida P, Massari F, Francolini G, Bertocchi F, Ferrari R, Rizzon P, Pitzalis MV.
    Am Heart J; 2003 Nov 20; 146(5):E17. PubMed ID: 14597946
    [Abstract] [Full Text] [Related]

  • 10. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA, VALIANT Investigators.
    Circulation; 2005 Nov 29; 112(22):3391-9. PubMed ID: 16301343
    [Abstract] [Full Text] [Related]

  • 11. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L, Iannazzo S, Zaniolo O.
    Am J Cardiovasc Drugs; 2009 Nov 29; 9(6):383-92. PubMed ID: 19929036
    [Abstract] [Full Text] [Related]

  • 12. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.
    Circulation; 2004 Oct 26; 110(17):2618-26. PubMed ID: 15492298
    [Abstract] [Full Text] [Related]

  • 13. Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant.
    White M, Ross H, Levesque S, Whittom L, Pelletier GB, Racine N, Meloche S, Voisin L.
    Ann Pharmacother; 2009 May 26; 43(5):831-9. PubMed ID: 19417110
    [Abstract] [Full Text] [Related]

  • 14. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group.
    Am J Kidney Dis; 2006 May 26; 47(5):751-60. PubMed ID: 16632013
    [Abstract] [Full Text] [Related]

  • 15. C-reactive protein in heart failure: prognostic value and the effect of valsartan.
    Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN, Val-HeFT Investigators.
    Circulation; 2005 Sep 06; 112(10):1428-34. PubMed ID: 16129801
    [Abstract] [Full Text] [Related]

  • 16. Valsartan in chronic heart failure.
    Ripley TL.
    Ann Pharmacother; 2005 Mar 06; 39(3):460-9. PubMed ID: 15687480
    [Abstract] [Full Text] [Related]

  • 17. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr 06; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

  • 18. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN.
    Circulation; 1999 May 25; 99(20):2658-64. PubMed ID: 10338459
    [Abstract] [Full Text] [Related]

  • 19. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
    Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN, Valsartan Heart Failure Trial Investigators.
    Circulation; 2002 Nov 05; 106(19):2454-8. PubMed ID: 12417542
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
    Clin Ther; 2005 May 05; 27(5):578-87. PubMed ID: 15978306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.